Edgar Filing: Corvus Pharmaceuticals, Inc. - Form 4

	maceuticals, Inc.									
Form 4 June 09, 201	7									
FORM									PPROVAL	
Check th	UNITED	Washington, D.C. 20549							3235-0287 January 31,	
Form 4 c Form 5 obligatio may con <i>See</i> Instr 1(b).	ger o 16. or Filed pu ins tinue. Section 170	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Krognes Steve E.			2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				of Earliest T Day/Year) 2017	ransaction		X Director Officer (give below)	e title $\frac{109}{below}$ Other	% Owner her (specify	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tah	le I - Non-I	Derivative	Securities A	Acquired, Disposed o	of. or Beneficia	llv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed Date, if	3.	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Rep	oort on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned directly	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e of (Month) ivative		4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 9.7	06/08/2017		А	15,000		<u>(1)</u>	06/08/2027	Common Stock	15,000	
Reporting Owners											
R	Reporting Owner Name / Address Director				Relationships 10% Owner Officer Other						
Krognes Steve E. C/O CORVUS PHARMACEUTICALS, INC. 863 MITTEN ROAD, SUITE 102 BURLINGAME, CA 94010											
Signa	tures										
/s/ Leiv Lea, as Attorney-in-Fact for Steve E. Krognes			teve E.	06/0	9/2017						

Edgar Filing: Corvus Pharmaceuticals, Inc. - Form 4

Explanation of Responses:

**Signature of Reporting Person

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on (1) the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming

Date

continuous service as a director until such vesting date. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays

a currently valid OMB number.